Literature DB >> 16923323

Reduced CREB phosphorylation after chronic lithium treatment is associated with down-regulation of CaM kinase IV in rat hippocampus.

Daniela Tardito1, Ettore Tiraboschi, Jiro Kasahara, Giorgio Racagni, Maurizio Popoli.   

Abstract

Lithium is widely used in the treatment of bipolar disorder, although its mechanism of action is not fully clear. This study was undertaken to assess the effects of prolonged lithium administration on cAMP responsive element-binding protein (CREB) phosphorylation and CaM kinase IV (CaMKIV), one of the main kinases phosphorylating CREB in neurons following synaptic activation. CREB total protein expression and phosphorylation (Ser133), as well as CaMKIV enzymatic activity, phosphorylation of Thr196 (the activator residue) and kinase expression level were assessed in total homogenates and nuclei from the hippocampus and prefrontal/frontal cortex following 5 wk lithium treatment. Whereas no significant effects were found in prefrontal/frontal cortex, lithium administration reduced CREB phosphorylation and at the same time down-regulated CaMKIV (enzymatic activity, phospho-Thr196 and protein expression level) in cell nuclei from the hippocampus. These data suggest for the first time the involvement of CaMKIV in the mechanism of action of lithium.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16923323     DOI: 10.1017/S1461145706007140

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  9 in total

Review 1.  Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects.

Authors:  Jorge A Quiroz; Rodrigo Machado-Vieira; Carlos A Zarate; Husseini K Manji
Journal:  Neuropsychobiology       Date:  2010-05-07       Impact factor: 2.328

2.  Transcriptome sequencing implicates dorsal striatum-specific gene network, immune response and energy metabolism pathways in bipolar disorder.

Authors:  R Pacifico; R L Davis
Journal:  Mol Psychiatry       Date:  2016-06-28       Impact factor: 15.992

Review 3.  Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Daniel C Mathews; Erica M Richards; Carlos A Zarate
Journal:  CNS Spectr       Date:  2013-03-11       Impact factor: 3.790

Review 4.  The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Bipolar Disord       Date:  2009-06       Impact factor: 6.744

5.  Enhancement by lithium of cAMP-induced CRE/CREB-directed gene transcription conferred by TORC on the CREB basic leucine zipper domain.

Authors:  Ulrike Böer; Julia Eglins; Doris Krause; Susanne Schnell; Christof Schöfl; Willhart Knepel
Journal:  Biochem J       Date:  2007-11-15       Impact factor: 3.857

6.  Lithium promotes DNA stability and survival of ischemic retinal neurocytes by upregulating DNA ligase IV.

Authors:  Ying Yang; Nandan Wu; Sijia Tian; Fan Li; Huan Hu; Pei Chen; Xiaoxiao Cai; Lijun Xu; Jing Zhang; Zhao Chen; Jian Ge; Keming Yu; Jing Zhuang
Journal:  Cell Death Dis       Date:  2016-11-17       Impact factor: 8.469

Review 7.  Cellular and molecular mechanisms in the long-term action of antidepressants.

Authors:  Giorgio Racagni; Maurizio Popoli
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

8.  Time-dependent biphasic modulation of human BDNF by antidepressants in neuroblastoma cells.

Authors:  Lorena Donnici; Ettore Tiraboschi; Daniela Tardito; Laura Musazzi; Giorgio Racagni; Maurizio Popoli
Journal:  BMC Neurosci       Date:  2008-07-05       Impact factor: 3.288

Review 9.  Implications and limitations of cellular reprogramming for psychiatric drug development.

Authors:  Brian T D Tobe; Michael G Brandel; Jeffrey S Nye; Evan Y Snyder
Journal:  Exp Mol Med       Date:  2013-11-15       Impact factor: 8.718

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.